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Objective:  To  present  the  international  consensus  for  recommendations  for  Ménière’s  disease  (MD)  treat-
ment.
Methods:  Based  on  a literature  review  and  report  of  4  experts  from  4  continents,  the recommendations
have  been  presented  during  the  21st  IFOS  congress  in  Paris,  in  June  2017  and are presented  in  this  work.
Results:  The  recommendation  is  to change  the lifestyle,  to use  the  vestibular  rehabilitation  in  the  inter-
critic  period  and  to propose  psychotherapy.  As  a conservative  medical  treatment  of  first  line,  the authors
recommend  to  use  diuretics  and  Betahistine  or  local  pressure  therapy.  When  medical  treatment  fails,
the  recommendation  is  to  use a second  line  treatment,  which  consists  in  the  intratympanic  injection  of
steroids.  Then  as a  third  line treatment,  depending  on the  hearing  function,  could be  either  the  endolym-
phatic  sac  surgery  (when  hearing  is  worth  being  preserved)  or the  intratympanic  injection  of  gentamicin
(with  higher  risks  of  hearing  loss).  The  very  last  option  is the destructive  surgical  treatment  labyrinthec-
tomy,  associated  or not  to cochlear  implantation  or vestibular  nerve  section  (when  hearing  is worth  being
preserved),  which  is  the  most  frequent  option.
© 2018  Elsevier  Masson  SAS.  All  rights  reserved.
1. Introduction
Ménière’s disease (MD) treatment must be first based on a
trustable diagnosis. To be confident with the diagnosis, it is rec-
ommended to use the consensual guidelines and classification of
the AAO-HNS published in 1995 [1] and recently reviewed by the
Equilibrium Committee in 2015 [2]. Although the diagnosis is pri-
marily based on the clinical history, clinicians also utilize various
tests to confirm the diagnosis before introduction of any treatment.
The next step is to tailor the treatment for each patient based on
an algorithm that seems frequently different from one center to
another in the same country, even in the same country. During the
last IFOS Congress in Paris in June 2017, an international consensus
(ICON) Round Table joining six experts of MD from different conti-
nents (Asia, America, Europe, and Australia) was designed in trying
to draw a minimal consensus, which could be summarized in an
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algorithm. But this synthesis revealed highly challenging, as among
the countries and/or continents of the participants of this ICON,
only two have drawn a consensus or recommendation applicable
in their countries, Japan in 2011 and France in 2016 [3]. Scientific lit-
erature was assessed using the Level of Evidence classification (1 to
5) and recommendations were given following the grading of rec-
ommendations assessment, development and evaluation (GRADE)
scoring system.
In MD,  the aim of the treatment is first to reduce the fre-
quency, and secondarily the severity, of the vertigo crises, with
a minimal impairment of hearing function, hoping this favor-
able result is associated with a hearing and tinnitus improvement
[4]. The treatment is symptomatic and should always be related
to the main complain of the patient. It must be conservative in
the first place. The conservative treatments are used whatever
the hearing function, as destructive ones are preferentially used
in patients with hearing loss. Concerning bilateral MD, the dif-
ficulty is the unilateral presentation at the beginning and the
delay of the contralateral involvement. That is why the treat-
ment should always be conservative. Caregivers must remember
the natural evolution of MD,  especially the resolution of vertigo,
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and the major implication of the placebo effect in any kind of
treatment.
Finally, the discussion before and during the congress between
participants of ICON Round Table has led to propose a minimal
intercontinental consensus on MD treatment, reported here. It
reviews the different therapeutic options for the unilateral form,
makes a focus on the bilateral form, and proposes a treatment
algorithm based on a review of the literature and the authors expe-
rience.
2. First step: medical treatment of Ménière’s disease
The authors recommend (Grade C), as the first care given to the
patient, the modification of the lifestyle including well sleeping [5]
(Level of proof 4), and a research of an obstructive sleep apnea
syndrome [6] (Level of proof 2), decreasing stress, avoiding caf-
feine, alcohol and tobacco [7] (Level of proof 4) and adopt a low
salt diet. Two treatment options should be considered to help the
patient: vestibular rehabilitation and psychotherapy [8–10] (Level
of proof 2). The vestibular rehabilitation should be avoided during
crises and preferentially used in intercritic period. The authors rec-
ommend this rehabilitation (Grade B) even if a recent Cochrane
review of the literature, using the risk of bias tool, cannot con-
clude on a positive effect of vestibular rehabilitation on balance
and dizziness-related quality of life [8]. But this review studied
the effects of vestibular rehabilitation in all unilateral peripheral
vestibular dysfunctions, including MD.  In this context, it reported
moderate to strong evidence that vestibular rehabilitation was  a
safe and effective management [9] (Level of proof 2). Considering
psychotherapy, especially the cognitive behavior therapy inter-
vention, it produces significant improvements in dizziness-related
symptoms, disability, and functional impairment among patients
with chronic subjective dizziness [10] (Level of proof 2).
Diuretics represent the most commonly used first-line medical
treatment. The drug chosen differs from one author to another but,
according to the literature, hydrochlorothiazide, acetazolamide and
chlorthalidone are used in decreasing order [11,12] (Level of proof
4). The authors recommend their use that may  decrease vertigo
spell frequency (Grade C). A special attention must be payed to their
respective contraindications and side-effects.
Betahistine is very popular in France, Europe, Japan and with
many surgeons in Australia but not FDA-approved in USA. The
dosage varies from one center to another but the literature reports
a better effect with a minimal dosage of 48 mg/d. It could be used up
to 288 to 480 mg/d for patient with severe MD  who does not suffi-
ciently respond to lower dosages [1–17] (Level of proof 1 and 3). The
authors recommend, depending on their country, using betahis-
tine at a dose of 48 to 96 mg/d (Grade C). Even if the side effects for
higher dosage seem rare and the efficacy better in some reports, the
authors do not give recommendation for these dosages for security
reason.
Another non-invasive option is the Meniett
®
system (Medtronic
Cie, the USA), producing sequences of micro-pressure pulses sus-
ceptible to act on the endolymphatic hydrops [18]. This device is
included of the algorithm treatment in Italy and Australia, even if
a recent Cochrane review concludes there is no evidence this ther-
apy is effective [19] (Level of proof 2). Because of the very low rate
of side effects reported in the five studies of the Cochrane review,
the authors recommend using this device as a first line treatment
(professional agreement).
3. Second step: intratympanic corticosteroids
At that point, after using one or all of these therapeutic options,
the authors confirm that 80% of patients are in remission of MD
symptoms, especially vertigo [20]. To manage conservatively the
rest of the patients, intratympanic injection of steroids (ITS) is pro-
posed as a second-line treatment. It is more and more popular [21].
Dexamethasone [22] is more used than methylprednisolone [23]
(Level of proof 2 for both). Patel et al. recently reported that two
injections of methylprednisolone (62.5 mg/mL) given 2 weeks apart
was safe and as efficient as gentamicin (40 mg/mL) used with the
same protocol to treat refractory MD.  Most authors use daily injec-
tions of dexamethasone solution (4 mg/mL) for five consecutive
days. For the authors, the use of one injection per week for 1 to 4
consecutive weeks is also efficient [24]. ITS significantly improves
both frequency and severity of vertigo spells compared to placebo
at 24 months after treatment (Level of proof 2). The authors rec-
ommend the use of ITS, whatever the drug, preferably with the
protocol previously described to treat patients with MD  in a non
ablative manner (Grade B) since these drugs are not ototoxic [25]
(Level of proof 1).
4. Third step: surgical conservative treatment
A literature review considering the studies published during the
last decade confirms a decline of surgical treatment of MD  in favor
of intratympanic injections [20]. The most favored surgical tech-
nique remains endolymphatic sac surgery (ELSS). It represents for
the authors one of the third-line treatments of MD,  even if it has
long been criticized and considered as a placebo surgery. Most crit-
ics referred on two placebo-controlled Danish studies analyzed in
the Cochrane review in 2010 and 2013. Both studies concluded that
ELSS has no evidence-based effect on natural course and vertigo
of MD [26,27] (Level of proof 2). But a more recent meta-analysis
came to the conclusion there was a low level of evidence in favor
of an effect [28] (Level of proof 2). This controversy is due to the
great difficulty to evaluate in a blinded way surgical treatments in
MD,  since the choice of a placebo or control reveals rather impossi-
ble. For most authors today, grommet insertion or mastoidectomy,
respectively chosen in the Danish studies, cannot be considered
as placebo treatments. Therefore the conclusion of these studies is
not relevant. This is underlined in the Cochrane review. Even if solid
proofs are lacking in the literature, the authors agree that it should
be the first option after failure of the medical conservative treat-
ment, if hearing function useful and MD in young subjects (Grade
B). All the authors favour ELSS but the evolution of the practice is
toward an increase number of ITS, especially in USA  and in France,
and a decrease number of ELSS surgeries.
5. Fourth step: medical destructive treatment of Ménière’s
disease
Intratympanic injection of gentamicin (ITG) is probably the most
effective non-surgical treatment to eradicate vertigo in MD.  But it
is also an ablative method that carries a non-negligible risk of hear-
ing loss [29] (Level of proof 2). Currently, ITG is favored in USA and
most European countries. But it is about to change, as in France,
Japan and Australia, ITS is preferred to ITG as a second-line treat-
ment. Concerning ITG, no consensus has been reached so far on the
dosage and treatment duration as Syed et al. has reported recently
in a review of the literature [24]. The authors recommend using
ITG as a destructive method preferentially when hearing function
is impaired for patients with good contralateral vestibular func-
tion (Grade A). Based on Syed et al. meta-analysis, is advocated a
“titration” protocol, ITG injections (40 mg/mL) being repeated until
disappearance of vertigo spells. This “tailored” protocol is about
to prevent hearing loss more than systematic weekly or monthly
injection [24,30] (Level of proof 2 and 4). As a systematic genetic
screening of MD patients is not currently done, hypersensitivity
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Fig. 1. Proposition of algorithm of treatment of Ménière’s disease.
to the aminoglycosides in carriers of the mitochondrial mutation
of the gene MTRNR1 is not screened. This mutation exposes to a
complete and definitive deafness after a single injection of amino-
glycosides [31]. ITG is now in transition between the third and the
fourth line of treatment of the MD.
6. Fifth step: surgical destructive treatments
Evidence-based evaluations of totally ablative techniques, rep-
resented by surgical labyrinthectomy and vestibular neurectomy
(VN) are scarce in the literature, compared to that of ELSS. No
randomized controlled trials are available in the literature. Nev-
ertheless, studies recommend their use after medical treatment
failure and report a very good efficacy to control vertigo in MD
patients. VN reveals more efficient than ITG [32,33]. The authors
recommend indicating VN in patients suffering of intractable ver-
tigo crises not influenced by medical treatment associated with
poor but serviceable hearing function for patients with good con-
tralateral vestibular function (Grade B). There is a trend to replace
ELSS by VN in patients that do not respond to ITG or suffer of drop-
attack crises. Surgical labyrinthectomy is less and less performed,
even if the efficacy is close to the VN, since it totally destroys the
remaining hearing function, at the difference with VN [34]. Most
authors recommend to associate cochlear implantation to surgical
labyrinthectomy in order to rehabilitate hearing in the same time.
This practice is more common in Australia and USA than in Europe
or Japan. It is not allowed in France.
7. Treatment of bilateral form of Ménière’s disease
Specific data concerning occurrence of bilateral MD are not
available and reports are from 2 to 47%. Bilateralization occurs sec-
ondarily after several years [35]. Obviously, bilateral MD  should be
treated in a conservative way to avoid bilateral deafferentation or
ablative treatments. This occurrence has to be anticipated at the
time of treating the first ear, especially when there are some argu-
ments to forecast that the contralateral ear is not spared. This is
the reason why  the conservative treatment has always to be used
for the first line, bringing more and more teams to switch from ITG
to steroids ITS. Concerning the surgical treatment, the best option,
even if controversial, is the ELSS in case of bilateral MD.
8. Proposition of algorithm of MD treatment
The Fig. 1 represents a proposal of an algorithm of MD  treatment
as an international consensus obtains for the IFOS meeting 2017.
The first line of treatment includes the medical conservative treat-
ment. After this line of treatment 80% of patients with MD are cured
or in remission. Then the second line is the IT injections, mainly ITS
as a conservative treatment and ITG in case of failure and preferen-
tially in patients with hearing impairment. After this second line, 90
to 95% of the patients are cured or in remission [36]. The third line
is the surgical, conservative or destructive, treatment. If indicated,
ELSS must be indicated before ITG.
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